Background: Patients with severe kidney disease and severe aortic stenosis requiring transcatheter aortic valve implantation (TAVI) represent a growing cohort. In this context, we investigated the feasibility and safety of a novel integrated approach, including gadolinium-free magnetic resonance tomography (MR) in order to minimize use of any contrast media (CM) in those patients.
Introduction
Transcatheter aortic valve implantation (TAVI) is now routinely performed in high-risk and intermediate-risk patients with low mortality-and complication rates. Although periprocedural risks have been substantially minimized since the introduction of TAVI, procedure-and contrast-induced acute kidney injury (AKI) remains a major concern [1, 2] .
In patients undergoing TAVI evaluation, contrast media (CM) is used for multislice computer tomography (MSCT) of the chest, abdomen and pelvis, left heart catheterization, aortography, and peripheral angiography [3] . Furthermore, a significant amount of CM is additionally administered during the actual TAVI procedure [4, 5] . Among patients undergoing TAVI requiring CM-based procedures, pre-existing CKD represents one of the major predictors for AKI [4, [6] [7] [8] .
We assessed the feasibility and safety of a novel integrated approach aiming to minimize periprocedural administration of CM and therefore reducing the AKI-risk in patients with severe CKD undergoing TAVI. In this context, we used gadolinium-free magnetic resonance tomography (MR), instead of MSCT for sinoannular and iliofemoral assessment and therefore valve selection. Moreover, we aimed to minimize administration of CM during coronary angiogram and TAVI in afflicted patients.
Methods

Study population
Consecutive patients undergoing TAVI for the treatment of severe symptomatic aortic stenosis between February 2016 and July 2017 were enrolled. All patients with severe CKD (glomerular filtration rate (GFR) <30 ml/min/m 2 ) were screened and managed with our integrated approach in order to minimize administration of CM (table 1) .
For the pre-procedural coronary angiogram and for TAVI itself, we aimed to reduce the amount of CM to a bare minimum. In addition, gadolinium-free MR was performed for annular and iliofemoral assessment, and valve sizing. Data were collected throughout the initial hospital stay and a clinical follow-up was conducted at 30 days post-procedure. The study complies with the declaration of Helsinki. Prospective data acquisition after TAVI was approved by the local ethic committee. All patients provided written informed consent.
TAVI work-up and MR protocols
Potential TAVI candidates were discussed by the interdisciplinary HeartTeam consisting of non-invasive cardiologists, interventional cardiologists, and cardiac surgeons.
For assessment of the coronary arteries, all patients underwent a pre-procedural coronary angiogram. In patients with severe CKD, only 2-4 injections using 2-6 ml of CM were performed to visualize the left and right coronary artery. The aortic root and the iliofemoral arteries were not visualized. Instead, for annular and iliofemoral measurements, a gadolinium-free MR was performed (examples are illustrated in figures 1 and 2). MRs were performed with a 1.5 T or 3 T scanner (Siemens Magnetom Aera or Siemens Magnetom Skyra, respectively, Siemens AG, Munich, Germany). For the assessment of the aortic annulus and aortic root a non contrast-enhanced navigator-gated 3-D whole heart acquisition during the diastolic phase was conducted using fast low angle shot (FLASH) gradientecho sequence with fat saturation and T2 preparation. The imaging parameters on the 3T scanner were as follows: repetition time/echo time 308.5/1.4 milliseconds, flip angle 20 degrees, bandwidth 610 Hz/pixel, field of view 300 × 400 mm, matrix 192 × 256, slice thickness 1.0mm, and voxel size 1.5 × 1.5 × 1.0 mm 3 . The imaging parameters on the 1.5 T scanner were as follows: repetition time 285.5/ echo time 1.5 ms, flip angle 90 degrees, bandwidth 590 Hz/pixel, field of view 240 × 320, matrix 173 × 256, slice thickness 0.8mm, and voxel size 1.4 × 1.2 × 0.8 mm 3 . A total of 44 overlapping slices were acquired. Double-oblique transverse views transecting through the most caudal attachments of all three native cusps were reconstructed to measure the annular perimeter and area with a 3-D reconstruction tool allowing for free navigation and image plane selection in the 3D data set (Merlin Diagnostic Workcenter, Phönix-PACS GmbH). Distances to the right and left coronary ostium was measured perpendicular to the annulus plane. Unenhanced MR angiography using a quiescentinterval single-shot (QISS) sequence was performed to assess suitability of iliofemoral access for transfemoral TAVI approach. The optimized QISS pulse sequence used the following imaging parameters: repetition time/echo time/ invertion time/ flip angle/ bandwidth = 667.6 ms / 1.74 ms / 345 ms / 111 degrees / 660 Hz/pixel. The acquisition matrix was 260 × 400/, field of view 260 × 400/mm, slice thickness 3/mm with slices overlap 0.6/, maintaining spatial resolution at 1 mm × 1 mm × 2.4 mm 3 / at 3 T and at 1.5 T, respectively. Two consecutive acquisition blocks from the infrarenal aorta to the proximal femoral arteries of overall 100 overlapping slices were acquired. Multiplanar reconstructions were derived in order to measure vessel diameters orthogonal to their longitudinal axis.
In patients without severe CKD, TAVI work-up was performed with MSCT of chest, abdomen and pelvis using standardized protocols [9, 10] .
TAVI procedure
The procedure was performed in conscious sedation in patients undergoing TAVI via the transfemoral approach and in general anesthesia for the transapical approach. We implanted the following valves: (1) ACURATE neo (Boston Scientific, Marlborough, Massachusetts), (2) SAPIEN 3 (Edwards Lifesciences, Irwine, California), (3) Evolut R (Medtronic Inc., Minneapolis, Minnesota) and (4) Allegra (NVT, Hechingen, Germany and Muri, Switzerland). Valve sizing was based on the annular perimeter (ACURATE neo, Evolut R or Allegra) or on the area (SAPIEN 3). 
Procedural modifications in patients with severe chronic kidney disease
In patients with severe CKD coaxial valve implantation angle was derived from MR and reassessed with injection of contrast media prior to valve implantation. For lowering the amount of CM during implantation, rapid pacing was performed to allow full visualization of the three cusps with approximately eight ml of CM. In patients with severe CKD, paravalvular regurgitation was assessed with transthoracic echocardiography instead of a supravalvular contrast injection. Following TAVI, patients' kidney function was closely monitored until creatinine was stable.
Definitions
Severe chronic kidney disease was defined as an estimated glomerular filtration rate (GFR) of less than 30 ml/min/ m 2 prior to TAVI. The estimation was performed using the Cockcroft-Gault equation. Clinical endpoints were defined according to the updated definitions of the Valve Academic Research Consortium VARC-2 11 . Acute kidney injury was defined as an increase in serum creatinine during the first seven days after valve implantation. Stage 1 was defined as an increase in serum creatinine to 150-200% compared with baseline or an increase in serum creatinine of 26.4 mmol/l (>0.3 mg/dl). Stage 2 was defined as an increase to 200-299% compared with baseline. Stage 3 was defined as an increase to 300% or more compared with baseline or serum creatinine of 354 mmol/l (4.0 mg/dl) with an acute increase of at least 44 mmol/l (0.5 mg/dl). Necessity of renal replacement therapy was considered as AKI stage 3.
Statistical analysis
Categorical variables are displayed as absolute numbers and percentages, and continuous variables are presented 
Results
From February 2016 to July 2017, 168 patients (55% women) with a mean age of 81±6 years were enrolled. A total of 20 patients (65% women) with severe CKD and without renal replacement therapy were treated using an integrated approach aiming to minimize contrast media. The other 148 patients (53% women) underwent standardized TAVI work-up and procedure, including MSCT. As highlighted in table 2, the baseline characteristics were balanced except for Society of Thoracic Surgeons Predicted Risk of Mortality and GFR.
Use of contrast media for TAVI work-up and procedure Use of contrast media is summarized in figure 3 . Pre-procedural coronary angiography was performed with 54±35 ml of CM in patients with severe CKD versus with 85±44 ml in patients without severe CKD (p <0.01). Patients without severe CKD underwent ECG-gated MSCT requiring 63±14 ml of CM. TAVI was performed with 40±32 ml and 112±50 ml of contrast media, respectively (p <0.01). The total amount of CM required for pre-procedural planning and TAVI was 94±54 ml in patients with severe CKD and 260±79 ml in patients without (p <0.01). 8%], p = 1.0) and major or life-threatening bleeding 1/20 (5%) and 11/148 (7.4%), p = 1.0, respectively) were similar in both groups. Early safety, clinical efficacy and device success endpoints at 30 days did not differ and were high in both groups. Kaplan Meier estimates of survival at 6 months were 100% and 93.8% in patients with and without severe CKD, respectively (log rank p = 0.31).
In-hospital outcomes
Discussion
We evaluated the feasibility of a novel integrated approach incorporating gadolinium-free MR instead of MSCT and administration of the bare minimum amount of CM in a cohort of patients with severe CKD and treated with TAVI. By applying this concept, we were able to reduce the total amount of CM by 64% in afflicted patients. Although the number of type 1 AKI was still slightly higher in patients with severe CKD, all other procedure-related risks appeared not to be impacted. This implicates that avoiding and reducing CM to an absolute minimum in TAVI patients is feasible and does not necessarily impact safety. Data are displayed as n (%) or mean±SD. CKD = chronic kidney disease; GFR = glomerural filtration rate; STS PROM = Society of Thoracic Surgeons Predicted Risk of Mortality To our very best knowledge, this study is the first to select prosthesis size solely based on gadolinium-free MR. MR provided sufficient quality for annular assessment in all patients. Notably, none of the patient had moderate or severe paravalvular regurgitation, there were no strokes and there was no mortality within 30 days in patients with severe CKD. Furthermore, MR provided sufficient quality for iliofemoral artery measurements in all patients. Therefore, gadolinium-free MR may be a valuable alternative imaging modality in patients with severe CKD.
Pathophysiology of acute kidney injury AKI following TAVI has been reported in 15-57% of patients [11] [12] [13] [14] . Intraprocedural episodes of hypotension, dehydration, administration of contrast media, or periprocedural bleeding may result in tubular ischemia. Furthermore, catheter manipulation and plaque rupture may result in dislodgement of plaques and cholesterol embolism [15] [16] [17] . In our study, the incidence of AKI in patients with severe CKD was 25%, but was mild (stage 1) in most. CKD may lead to chronic inflammation, oxidative stress, sympathetic nerve overactivity and thrombogenic factors thus accelerating the atherosclerotic process [18] [19] [20] [21] . Several studies have confirmed that AKI is a strong predictor for short-and long-term mortality after TAVI [7, [22] [23] [24] [25] .
In our study including a limited number of patients with severe CKD, 30 day and 6 months survival rates were excellent.
Relevance of contrast media
The reported incidence of contrast-induced nephropathy in an unselected group of patients undergoing invasive catheterization was approximately 15% [26, 27] . In patients with additional risk factors, this incidence increased to 50% or more [28] . Previous publications have shown that administration of 100 ml contrast media for coronary interventions was associated with an increased risk of contrast-induced nepropathy, and even mortality [26, 29, 30] . Recent trials reported an average amount of contrast media for TAVI between 90 ml and 220 ml [4, 31] , whereas a significant amount of CM may be additionally required for procedural planning. Using our integrated protocol in selected TAVI patients with impaired renal function may allow physicians to minimize the amount of administered CM and consequently mitigate the risk of AKI.
MR for valve selection
Correct sizing of the aortic annulus is crucial for successful valve implantation [32] . Bernhardt et al. suggested that non-enhanced MR may be used as an alternative imaging modality with similar accuracy compared to MSCT for aortic annulus measurements [33] . In the current literature is a small case series published with five patients with severe CKD who underwent TAVI without prior MSCT [34] .
Valve sizing was based on echocardiography, aortography, calcification on fluoroscopy as well as weight and height of the patient and TAVI seemed to be feasible without prior dedicated imaging. The present study is the first where valve size was chosen by solely relying on MR measurements. We used a 3 dimensional MR approach with individual reconstruction of the aortic annulus at the level of the lowest hinge points of the cusps. This way, valve sizing was feasible in all patients undergoing MR. The main expected difference of MR compared with MSCT is that calcifications appear as a negative signal which can lead to an underestimation of annular and leaflet calcification with MR. In our study we used self-expanding valves in almost all patients to reduce the risk of annular rupture. Only one patient with a large aortic annulus was treated with a Sapien 3 29 mm. Interestingly, Pulerwitz et al. showed in 52 patients that MSCT with 20 ml of contrast media was in most patients of diagnostic quality for preprocedural TAVI planning [35] . Using a low contrast media MSCT protocol could be an alternative approach in patients with severe chronic kidney disease undergoing TAVI. Procedural success matched with patients who underwent pre-TAVI evaluation with a standardized MSCT protocol.
Study limitations
First, this is a relatively small, observational study lacking a control arm. Second, applicability of our integrated approach to other TAVI patients remains unknown and needs to be determined. Finally, we report a single-center experience and more prospective studies evaluating this and similar strategies are warrented.
Conclusion
In patients with severe CKD requiring TAVI, using gadolinium-free MR instead of MSCT for pre-procedural planning and periprocedural reduction of CM to a bare minimum appears feasible and safe in patients undergoing TAVI with self-expanding valves. When compared to regular TAVI patients, this integrated approach may allow a CM reduction of 64% (260±79 ml versus 94±54 ml). In this context, our study highlights that gadolinium-free MR renders adequate image quality enabling detailed TAVI procedure planning, including aortic annulus and iliofemoral arteries assessment, and finally selection of the most appropriate aortic valve prosthesis. To our best knowledge, this has not yet been described elsewhere.
